NASDAQ:CODX Co-Diagnostics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Co-Diagnostics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.83 +0.52 (+3.63 %) (As of 09/18/2020 12:24 PM ET) Add Compare Share Today's Range$14.10Now: $14.83▼$14.9950-Day Range$8.24MA: $16.46▼$30.8052-Week Range$0.85Now: $14.83▼$30.99Volume23,802 shsAverage Volume7.88 million shsMarket Capitalization$416.47 millionP/E Ratio82.39Dividend YieldN/ABeta-3.46 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCo-Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $31.50, Co-Diagnostics has a forecasted upside of 113.6% from its current price of $14.75.Amount of Analyst CoverageCo-Diagnostics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesCo-Diagnostics has received 250 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCo-Diagnostics has received 277 “underperform” votes. (Add your “underperform” vote.)Community SentimentCo-Diagnostics has received 52.56% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Co-Diagnostics and other stocks. Vote “Outperform” if you believe CODX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CODX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCo-Diagnostics does not currently pay a dividend.Dividend GrowthCo-Diagnostics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Co-Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.00% of the stock of Co-Diagnostics is held by insiders.Percentage Held by InstitutionsOnly 23.87% of the stock of Co-Diagnostics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Co-Diagnostics are expected to grow by 20.37% in the coming year, from $1.62 to $1.95 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Co-Diagnostics is 81.94, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 19.00.Price to Earnings Ratio vs. SectorThe P/E ratio of Co-Diagnostics is 81.94, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.90.Price to Book Value per Share RatioCo-Diagnostics has a P/B Ratio of 147.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.43 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CODX Previous Symbol CUSIPN/A CIK1692415 Webwww.codiagnostics.com Phone801-438-1036Debt Debt-to-Equity RatioN/A Current Ratio11.57 Quick Ratio8.18Price-To-Earnings Trailing P/E Ratio82.39 Forward P/E Ratio9.15 P/E GrowthN/A Sales & Book Value Annual Sales$220,000.00 Price / Sales1,893.05 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book148.30Profitability EPS (Most Recent Fiscal Year)($0.36) Net Income$-6,200,000.00 Net Margins31.42% Return on Equity56.17% Return on Assets51.41%Miscellaneous Employees39 Outstanding Shares28,083,000Market Cap$416.47 million Next Earnings Date11/11/2020 (Estimated) OptionableNot Optionable $14.83 +0.52 (+3.63 %) (As of 09/18/2020 12:24 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CODX News and Ratings via Email Sign-up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter. Co-Diagnostics (NASDAQ:CODX) Frequently Asked Questions How has Co-Diagnostics' stock been impacted by COVID-19? Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CODX stock has increased by 11.2% and is now trading at $14.67. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Co-Diagnostics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Co-Diagnostics. When is Co-Diagnostics' next earnings date? Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020. View our earnings forecast for Co-Diagnostics. How were Co-Diagnostics' earnings last quarter? Co-Diagnostics Inc (NASDAQ:CODX) posted its earnings results on Thursday, August, 13th. The company reported $0.43 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.59 by $0.16. The business had revenue of $24.04 million for the quarter, compared to the consensus estimate of $27 million. Co-Diagnostics had a return on equity of 56.17% and a net margin of 31.42%. View Co-Diagnostics' earnings history. What price target have analysts set for CODX? 2 analysts have issued 1 year price objectives for Co-Diagnostics' stock. Their forecasts range from $30.00 to $33.00. On average, they expect Co-Diagnostics' stock price to reach $31.50 in the next year. This suggests a possible upside of 114.7% from the stock's current price. View analysts' price targets for Co-Diagnostics. Are investors shorting Co-Diagnostics? Co-Diagnostics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 7,850,000 shares, an increase of 18.0% from the August 15th total of 6,650,000 shares. Based on an average trading volume of 3,850,000 shares, the days-to-cover ratio is presently 2.0 days. View Co-Diagnostics' Short Interest. Who are some of Co-Diagnostics' key competitors? Some companies that are related to Co-Diagnostics include Cardiovascular Systems (CSII), Atrion (ATRI), Luminex (LMNX), Cerus (CERS), Acutus Medical (AFIB), Orthopediatrics (KIDS), GenMark Diagnostics (GNMK), OraSure Technologies (OSUR), Invo Bioscience (IVOB), Vapotherm (VAPO), MiMedx Group (MDXG), SI-Bone (SIBN), LeMaitre Vascular (LMAT), Cryolife (CRY) and Tactile Systems Technology (TCMD). View all competitors. What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Moderna (MRNA), Gilead Sciences (GILD), Ibio (IBIO), Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ) and Tesla (TSLA). Who are Co-Diagnostics' key executives? Co-Diagnostics' management team includes the following people: Mr. Dwight H. Egan, Chairman, CEO & Pres (Age 67, Pay $295k)Dr. Brent C. Satterfield, Co-Founder & Chief Science Officer (Age 43, Pay $237.5k)Mr. Reed L. Benson, CFO & Sec. (Age 72, Pay $215k)Dr. Mayuranki Almaula, Sr. VP of Overseas Operations & Strategic AlliancesMr. Cameron Gundry, Head of Commercialization LATAM/EUR When did Co-Diagnostics IPO? (CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO. What is Co-Diagnostics' stock symbol? Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX." Who are Co-Diagnostics' major shareholders? Co-Diagnostics' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.74%), Nuveen Asset Management LLC (0.79%), Barclays PLC (0.53%), Bank of New York Mellon Corp (0.36%), Advisory Services Network LLC (0.26%) and Virtu Financial LLC (0.25%). Company insiders that own Co-Diagnostics stock include Eugene Durenard and Richard S Serbin. View institutional ownership trends for Co-Diagnostics. Which major investors are buying Co-Diagnostics stock? CODX stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Nuveen Asset Management LLC, Barclays PLC, Bank of New York Mellon Corp, Virtu Financial LLC, Charles Schwab Investment Management Inc., California Public Employees Retirement System, and Swiss National Bank. View insider buying and selling activity for Co-Diagnostics. How do I buy shares of Co-Diagnostics? Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Co-Diagnostics' stock price today? One share of CODX stock can currently be purchased for approximately $14.67. How big of a company is Co-Diagnostics? Co-Diagnostics has a market capitalization of $411.98 million and generates $220,000.00 in revenue each year. The company earns $-6,200,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Co-Diagnostics employs 39 workers across the globe. What is Co-Diagnostics' official website? The official website for Co-Diagnostics is www.codiagnostics.com. How can I contact Co-Diagnostics? Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84124. The company can be reached via phone at 801-438-1036 or via email at [email protected] This page was last updated on 9/18/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
